Cookie Policy - To find out more about cookies on this website, see our privacy policy

Cookie Policy

We Help Companies Find New Sales Opportunities

We Help Companies Find New Sales Opportunities

Chemicals & Pharmaceuticals - 2007






















Medical House is to sell its Eurocut subcontract engineering subsidiary to Semes for up to £3.7m, in order to focus on its drug delivery division.

Pharmalicensing, the York-based life sciences and biopharmaceutical technology transfer firm, is to be acquired by UTEK Corporation for £1m.

Vindon Healthcare, the pharmaceutical services firm, has appointed Wilson Bowden to build a new £3.3m 29,000 sq ft factory and storage facility at the Kingsway Business Park in Rochdale by autumn 2008.

GlaxoSmithKline is to invest £50m in the development of a new neuroscience research centre at Shanghai in China by the end of next year.

Dechra Pharmaceuticals is planning to acquire VetXX, the Danish supplier of veterinary products with 165 staff, for £62m.

Personal Screening has acquired the web portal for £0.1m, in order to expand its online sales of medical testing kits and other health products.

Inverness Medical Innovations has acquired BBI Holdings, the diagnostic tests manufacturer with sites in Cardiff, Swansea and Dundee, for £84m.

Reckitt Benckiser is to acquire Adams Respiratory Therapeutics, the US pharmaceuticals company, for £1.1bn, as part of a strategy to create a global over-the-counter medicines business.

The Specials Laboratory is looking to expand the 145-strong workforce at its Northumberland-based pharmaceuticals business with 23 new staff.

Bionostics, the Oxford-based medical diagnostics group, is to be acquired by NAV Bidco for £15m.

Focus Pharmaceuticals, the Burton-based supplier of prescription generic pharmaceuticals with 15 staff, has undergone a £3.2m management buy-out backed by Matrix Private Equity.

Concateno is to relocate its drugs testing business and up to 100 jobs from London and Warrington to Milton Park, near Didcot, by next May.

ClinTec International is planning to set up a new headquarters for its clinical research business in Glasgow, with the creation of 240 jobs over the next three years.

Genus is to sell its Animalcare veterinary pharmaceuticals business to Ritchey for up to £14m.

Sanofi Aventis, the pharmaceuticals company, is planning to relocate its Guildford headquarters in 2009 and is seeking a suitable 80,000 sq ft site in the Thames Valley.

Ashton Pharmaceuticals, the Manchester-based drugs manufacturer with 280 staff, has been bought out of administration by Recipharm of Sweden for undisclosed terms.

GlaxoSmithKline has acquired Reliant Pharmaceuticals, the US supplier of cardiovascular medicines, for £798m.

United Drug has acquired Procon Conferences, the Harrogate-based pharmaceutical conference services company with 28 staff, for £4.2m.

Creative Outsourcing Solutions International has been bought of administration by Dutch firm Budelpack, securing the future of 560 jobs at its cosmetics factory near Bridgend, but up to 180 jobs will be lost in Littlehampton.

One NorthEast is to help fund the development of a new training centre for the chemical industry, with the creation of 25 jobs, and a number of potential sites in Teesside will be considered.

Synexus, the Chorley-based drug trials company with 150 staff, is to be acquired by private equity firm Lyceum Capital for £18m.

Henkel is considering plans to close a number of chemical plants and shed thousands of jobs after completing the £2.7bn acquisition of the National Starch adhesives business from ICI early next year.

Almac Sciences is looking to double the 25 staff at its production and research site at Elvingston Science Centre in East Lothian, while its Irish parent company is to set up a new US headquarters in Pennsylvania.

Lancashire Chemical Works, the Derbyshire-based chromium chemicals supplier with 40 staff, has undergone a management buy-in backed by the Endless buy-out fund.

Bio-Stat, the Stockport-based healthcare products group with 70 staff, has been acquired by Inverness Medical Innovations of the US for up to £24m.

Genus has raised £19m in a share placing, in order to reduce debt and fund the development of its animal genetics business.

Augean has acquired RNA Investments, the Avonmouth-based chemicals and solvents recycling company that trades as Chemical Recoveries, for £5.8m.

Northern Recruitment Group is planning to expand its staffing levels in Middlesbrough from 12 to 40 over the next 18 months, in response to rising demand from the chemical industry.

Norbrook Laboratories is to invest £83m in the expansion of its veterinary pharmaceuticals research and development business in Newry, with the creation of up to 293 jobs by 2013.

Renovo is to relocate its Manchester-based medical research business to a new 25,000 sq ft site at the University of Manchester Incubator Company's core technology facility by the end of the year.

Human Recognition Systems has secured a £2m investment from Capital Values Group to help fund the expansion of its Liverpool-based biometrics business, and the 24 staff are relocating to a new site at Wavertree Technology Park.

AAI Pharma is to expand its drug industry support business in Edinburgh over the next three years, including a new site in the Riccarton area and the creation of up to 47 scientific and administration jobs.

Solvay is to sell its caprolactone chemicals business in Warrington to Perstorp Group of Sweden for £140m, with the transfer of 65 staff.

United Drug has acquired Alliance Healthcare Information, the US pharmaceutical sales and marketing services company with 163 staff, for £4.6m.

Wynnstay has acquired MVZ Farm Supplies, the Droitwich-based animal healthcare products distributor, for an initial £0.5m.

Biofusion has sold its 50% stakes in Cardiff ProTides and Cardiff Biologicals to Morvus Technology, leaving it with a portfolio of 23 companies from partnerships with universities in Sheffield and Cardiff.

York Pharma has acquired Derms Development, the dermatology company that owns Cheshire-based Crawford Healthcare and employs a medical sales force of 53, for £17m.

Shire is to sell a portfolio of dermatology products sold in the UK, France, Germany, Italy, Spain and Ireland to Almirall for £104m, in order to focus on its main biopharmaceuticals business.

Wyeth is to acquire Haptogen, the Aberdeen-based biopharmaceutical therapies company with 30 staff, for an estimated £25m.

E-Therapeutics is planning to raise up to £5m in a share placing to fund the expansion of its Tyneside-based drugs development business.

Avecia Biologics is creating about 20 new research and development jobs, following a £1m investment in new laboratory facilities at its site in the Tees Valley.

Mentholatum is to invest £10m in the expansion of its non-prescription medicines and healthcare products factory in East Kilbride, and the 80-strong workforce will grow by about 25%.

Norfolk Lavender, the Norfolk-based fragrance supplier with 55 staff, is to merge its wholesale marketing and distribution business with Gleneagles of Edinburgh.

The Medical Research Council has unveiled proposals to build a £350m medical research laboratory on a 3.5-acre site being sold by the government near the British Library in London, in partnership with the Wellcome Trust, UCL and Cancer Research UK.

Biotec Distribution Wales is to set up a new £1.5m drug development centre in Bridgend by next April, with the creation of 27 jobs.

Dundee University is to invest £6m in a new Division of Molecular Medicine at the College of Life Sciences, including new laboratory facilities and the creation of about 100 jobs.

Aesica has finalised the acquisition of the Abbott pharmaceuticals factory in Queenborough, Kent, securing the future of 450 staff.

SABIC UK Petrochemicals has submitted plans to build a new £200m polypropylene plant at Wilton on Teesside, but may still decide to locate the project elsewhere.

Bee Health is to create up to 50 new jobs at its factory in Bridlington, having won approval to supply Halal vitamins and supplements to Malaysia.

Gilead Pharmaceuticals is to set up a new 43,000 sq ft office at Stockley Park in west London.

Universal Sensors, the Cambridge-based developer of biosensor technology to detect drugs, is planning to expand its workforce from eight to 40 over the next year.

Concateno is to acquire Cozart, the Abingdon-based drug testing firm, for £64m, funded by a £54m share placing.

Croda International has sold its Refrigeration Lubricants business to Lubrizol for £62m, with the transfer of a small number of sales and technical staff.

Quotient BioResearch is to acquire Alba Bioscience, the Edinburgh-based company with 60 staff, from the Scottish Blood Transfusion Service for undisclosed terms.

MDY Healthcare is to provide up to £3m in loan capital to finance a joint venture with William Ransom & Son, in order to supply natural healthcare products to consumers via the internet, mail order and telesales.

Kendle is to relocate its Edinburgh-based clinical research business and 100 staff to a 14,200 sq ft unit at the Technopole science park.

St Andrews ChemTech International, the Fife-based chemical technology company with 16 staff, has undergone a management buy-out.

Aesica is planning to create about 40 jobs at a new £10m pharmaceuticals outsourcing factory in Northumberland over the next few years, while 15 new jobs will be created at its North London factory by the end of the year.

Chimatica has secured "significant" funding from NatWest to expand its Liverpool-based pharmaceuticals research outsourcing business.

Medical House has sold its SQ-PEN needle-free insulin injector business to Diabetes Management International for an initial £0.7m.

Zi Medical is to sell its St Asaph-based Zimed medical infusions business to a new company called Zimed Holdings for an initial £1.2m.

ICI has acquired Advanced Applied Adhesives of the US, in order to expand its Electronic Materials division.

Q Chip has secured a £2m equity investment to fund the expansion of its Cardiff-based drug delivery and DNA testing technology business.

ICI, the speciality chemicals manufacturer, is to accept a £8bn takeover offer from Akzo Nobel of the Netherlands.

Omega Diagnostics has raised £2.2m in a share placing to fund the acquisition of Genesis-CNS, the Cambridgeshire-based nutritional sciences company with 25 staff, in a £6.7m reverse takeover.

Immunodiagnostic Systems is to acquire Biocode Hycel, the Belgian diagnostics company, for £15m.

Co-operative Group is to invest £20m in the development of a prescription drugs manufacturing plant in Tianjin, China, in a joint venture with Tasly Group that will give it greater control over its supply chain.

ReNeuron Group is to acquire AmCyte, the US cell therapy company, for £2m, including cell encapsulation technology, laboratories and staff.

SLG Beauty is to relocate its cosmetics manufacturing business and 65 staff from Leominster to a 60,000 sq ft factory in Gloucester in December.

ICI is to acquire the Dulux paints business in South Africa from AECI for £52m, including subsidiaries in Botswana, Zambia, Swaziland, Malawi and Namibia.

Reckitt Benckiser is to sell Hermal, its prescription skincare business, to Laboratorios Almirall of Spain for £255m.

Premier Research Group has acquired ARS of the US for £11m and D-Target of Switzerland for £7m, in order to expand its clinical research business.

Huntsworth has acquired AXIS Healthcare Communications, the US provider of services to pharmaceutical and medical device companies with 200 staff, for an initial £9m.

Concateno has acquired CPL International, the Liverpool-based provider of alcohol and drug testing services, for £0.8m.

Huntsman, the chemicals manufacturer with 650 staff at sites in Hartlepool, Wilton, Haverton Hill and Billingham, is to be acquired by Hexion for £5.3bn, which beats a rival offer from Basell.

Renishaw has acquired a 75% stake in D3 Technologies for £1.8m, in order to develop University of Strathclyde technology for the detection of genetic predisposition to disease.

Tepnel Life Sciences has acquired Wildlife DNA Services and Food DNA Services, the North Wales-based providers of genotyping and food analysis services.

NeutraHealth has acquired Health Products for Life, the online supplier of vitamins and supplements, for £0.5m.

Immunodiagnostic Systems is to acquire Nordic Bioscience Diagnostics of Denmark for £17m and production of diagnostic testing kits will transfer from Copenhagen to Tyneside.

Cleveland Potash is to invest £20m at the Boulby potash mine in East Cleveland, in order to extend its life by at least 20 years and secure the future of 1,000 jobs.

The Medical Research Council is considering plans to relocate some of its facilities from Mill Hill in Hertfordshire to a £200m "super centre" or a number of smaller sites in London.

Roar Particles has raised £1.3m from private investors to fund the expansion of its nanotechnology and fingerprint analysis business.

BioProgress is to acquire Melbrosin, the supplier of natural health products with 52 staff in Germany, Italy, Austria and the UK, for up to £24m.

Brunner Mond has secured planning permission to build a new £10m sodium bicarbonate plant at Lostock in Northwich by 2009, with the creation of 14 jobs.

Intertek has acquired Quantitative Technologies, the US pharmaceuticals testing company, for £10m.

Medical Solutions is to acquire Geneservice, the Cambridge-based supplier of genomic products and services to the life sciences sector, for £3.9m.

Quintiles is to set up a new £7.5m pharmaceuticals research centre at the Alba Campus in Livingston, with the creation of 150 jobs.

Integrin Advanced Biosystems has acquired Biobest, the Penicuik-based virology, serology and DNA diagnostics company, for £2.8m.

Vickers Laboratories is to expand the distribution facilities at its speciality chemicals business in Leeds with the creation of four jobs, and a new laboratory will be set up.

The University of Edinburgh has announced plans to open a £4.3m Centre for Human & Avian Influenza Research in September, in order to develop new ways to control major flu outbreaks.

Sanofi Aventis is investing £12m in the expansion of its pharmaceuticals plant in Newcastle-upon-Tyne, securing the future of 500 jobs.

Concateno is to acquire Marconova, the Swedish drug and alcohol testing company, for £2m.

BioProgress has acquired PharmaHerb, the vitamin and nutritional products supplier, for £0.6m.

The Specials Laboratory is to create 15 new jobs at its Northumberland-based pharmaceuticals business, taking the workforce to 150.

Napp Pharmaceuticals is planning to expand its headquarters at the Cambridge Science Park, with the signing of a prelet on 120,000 sq ft of office space in three adjacent buildings.

Reckitt Benckiser, the cleaning products manufacturer, is said to be looking to relocate staff from two offices in Slough, having appointed DTZ to find a suitable 200,000 sq ft site in the Thames Valley.

Elementis is to sell its global pigments division to Rockwood Specialities Group of the US for £70m, in order to reduce debt.

Scottish Enterprise has announced a tie-up with Alexandria Real Estate Equities for the development of a £250m life sciences research centre next to Edinburgh Royal Infirmary, which is expected to create 6,500 jobs.

United Drug has acquired Craig & Hayward, the Oxfordshire-based medicines supplier with 13 staff and net assets of £1.2m.

ICI is to acquire Dongsung Chemical, the South Korean adhesives manufacturer, for £15m.

Intercytex is to raise £12m in a share placing to fund the expansion of its Cambridge-based cell therapy business.

Penn Pharmaceuticals, the Tredegar-based contract manufacturer with more than 200 staff, has undergone a £67m management buy-out backed by Lloyds Development Capital.

Dechra Pharmaceuticals has acquired Leeds Veterinary Laboratories, the Leeds-based supplier of veterinary diagnostic tests with 18 staff, for £0.8m.

E-Therapeutics has raised an undisclosed seven-figure sum to fund the expansion of its Tyneside-based drug discovery business, which currently employs 18 staff, and is also considering plans for a flotation.

York Pharma has acquired Rosanto Pharmaceuticals for £2m, and has also raised £5.3m in a share placing to fund the commercial development of skin care products.

AstraZeneca is to acquire MedImmune, the US biotechnology company that is developing about 45 experimental drugs and flu vaccines and has almost 3,000 staff, for £7.7bn.

Dundee Cell Products has secured a six-figure cash injection from the Discovery Investment Fund to develop manufacturing and research facilities for its life sciences business at the Dundee University Incubator.

Bespak is to acquire Emergent Respiratory Products, the US supplier of breathing equipment, for up to £19m.

United Drug has acquired the pharmaceuticals and healthcare packaging services division of Budelpack International of Belgium, with the transfer of 140 staff.

Maelor has acquired Acorus Therapeutics, the Bishop Auckland-based pharmaceuticals and medical devices company, for £13m.

BBI is planning to expand its diagnostic test kit manufacturing facilities in Dundee, with the creation of 27 new jobs over the next three years.

Concateno has acquired Euromed, the London-based provider of drug testing devices with 13 staff, for £12m.

Cambridge Antibody Technology is to set up a new 92,000 sq ft research and manufacturing centre at Granta Park in Cambridge by 2008, as part of an expansion programme that will create 300 jobs.

BBI has acquired Theratase, the enzyme manufacturer with sites in Blaenavon, London and South Africa, for £24m.

Oxeco is to acquire Oxray, the Oxford-based start-up company involved in molecular structure determination services, for £2m.

Cognia, the US life sciences company, is to set up a new European operations centre at its site in Edinburgh, with the creation of 75 jobs.

VASTox has acquired DanioLabs, the Cambridge-based drug discovery company with 37 staff, for £15m, as well as Dextra Laboratories, the Reading-based carbohydrate chemistry services company with 17 staff, for £1.5m.

Fulcrum Pharma is to acquire Unicus Regulatory Services, the Wokingham-based pharmaceutical regulatory consultancy, for up to £5m.

Gentronix has secured a £1.4m investment from NVM Private Equity and existing backers to fund the recruitment of a global sales team for its Manchester-based biotechnology business.

Morvus Technology is to create 54 jobs at a new 14,000 sq ft pharmaceuticals research centre at the National Botanical Garden in Carmarthenshire over the next three years.

Akcros Chemicals has been sold by Akzo Nobel to investment firm GIL Investments for undisclosed terms, including 160 staff at sites in Manchester and the US.

Paradigm Therapeutics, the Cambridge-based pharmaceuticals company with 70 staff, is to be acquired by Takeda of Japan in a multi-million pound deal.

Oxford Biomedica has acquired Oxxon Therapeutics, the Oxford-based therapeutic vaccines company, for £16m.

The University of Aberdeen is planning to set up a £2.2m life sciences centre in partnership with Scottish Enterprise Grampian and Aberdeen City Council, with the creation of 200 jobs.

AstraZeneca has announced plans to invest a further £4.3m in the expansion of its pharmaceuticals testing laboratory in Brixham, Devon, by 2008.

British Vita is to sell its Hyperlast and Autothane elastomer systems operations to Dow Polyurethanes for undisclosed terms, including 170 staff in Derbyshire and Wrexham.

Tor Coatings, the Wearside-based paint and adhesives manufacturer with 193 staff, has been acquired by RPM International of the US.

BioProgress has acquired DMPL, the French pharmaceuticals marketing company, for £0.3m.

Cozart has acquired Nemesis Scientific, the provider of workplace drug testing services with 86 collection agents and offices in Wakefield and Swindon, for £1.1m.

Neuropharm is planning to raise £20m in a flotation on Aim to fund the development of drugs for disorders of the central nervous system.

UCB is planning to create a further 100 pharmaceutical research jobs at its site in Slough, to add to the existing 805 staff.

Millennium Chemicals, the Stallingborough-based titanium dioxide manufacturer with 420 staff, is being sold as part of a £612m deal between Cristal of Saudi Arabia and current owner Lyondell.

Treatt has acquired a 50% stake in Earthoil, the Lichfield-based supplier of organic essential oils and vegetable oils, for £2.5m.

Hays has acquired James Harvard, the London-based recruitment company specialising in the pharmaceutical and biotechnology sectors, for an initial £24m.

McBride is to acquire Chemolux, the Luxembourg-based household products manufacturer with a site in Coventry and 120 UK-based staff, from Henkel for up to £39m.

AstraZeneca is to shed 700 of the 2,500 jobs at its pharmaceuticals factory in Macclesfield over the next three years, but has also announced plans to invest £63m in a new laboratory at the site.

Shire is to acquire New River Pharmaceuticals of the US for £1.3bn, in order to gain control of Vyvanse, a new drug for attention deficit hyperactivity disorder.

McBride has acquired Dasty Italia, the Italian manufacturer of household cleaning liquids with about 100 staff, for £19m.

BioCity, the Nottingham-based bio-science incubation centre, is planning a £5m expansion project, in order to offer an additional 40,000 sq ft of laboratory space by the end of the year.

TrichoTech, the Cardiff-based drugs testing company, has been acquired by investment firm Concateno for £11m.

AstraZeneca is to acquire Arrow Therapeutics, the London-based biotechnology company with 57 staff, for £76m, and has also announced plans to shed 3,000 jobs over the next three years.

The Scottish Funding Council has announced a £77m alliance between the universities of Aberdeen, Dundee, Edinburgh, Glasgow, Strathclyde and St Andrews to collaborate in life sciences research, with the creation of 18 research and 24 support jobs.

HFL, the Newmarket-based sports forensic testing company with 130 staff, has been sold by the Horserace Betting Levy Board to the Quotient BioResearch consortium of investors for £20m.

NeutraHealth is to acquire Brunel Healthcare, the Bristol-based supplier of vitamins and supplements, for an initial £4m.

ClinPhone is planning to expand the 452-strong workforce at its Nottingham-based clinical trials technology business with 80 additional staff over the next 12 months.

Alliance Boots is to set up a £3m Boots Centre for Innovation at Swansea University's Institute for Life Science, in order to help researchers and entrepreneurs develop new pharmaceutical products.

Wyeth Pharmaceuticals is considering plans to relocate its UK headquarters from Maidenhead to a 100,000 sq ft site at Green Park in Reading.

Cellartis of Sweden is planning to set up a £9m biotechnology research centre in Dundee, with the creation of up to 75 jobs.

Huntsman is to invest £11m in the expansion of its adhesives factory in Duxford, Cambridgeshire, with the creation of 15 new jobs.

Creative Outsourcing Solutions International is to expand its cosmetics factory in Maesteg over the next three years, with the creation of 300 jobs, but 240 jobs will be lost at its site in Littlehampton.

The University of Edinburgh has secured a £24m Scottish Executive grant to set up a £59m stem cell science and regenerative medicine centre, housing up to 220 academic researchers.

Skyepharma is to sell its injectable drugs business to Blue Acquisition for up to £42m, in order to focus on its Flutiform asthma treatment, and has also announced plans to raise £15m in a share placing.

Protherics has raised £38m in a share placing to fund the expansion of its biotechnology business, including the acquisition of US-based MacroMed and licensing deals with Glenveigh Pharmaceuticals and Advanced In Vitro Cell Technologies.

Almac Pharma Services is to create 60 new jobs at its site in Craigavon, following a £5.4m investment in new pharmaceutical research facilities.

Altrix, the Warrington-based drug testing firm with 54 staff, has been acquired by Concateno for £11m.

GlaxoSmithKline is to acquire Praecis Pharmaceuticals, the US biopharmaceuticals company, for £28m.

Norman Hay has acquired a 75% stake in Tam International, the Daventry-based supplier of sealant, chemical solutions and application equipment to the construction industry, for £1.7m.

ProStrakan has sold its ProSkelia drug discovery business in France to Galapagos of Belgium for £8.4m.